<DOC>
	<DOCNO>NCT00374803</DOCNO>
	<brief_summary>To determine safety efficacy new formulation Myfortic combination tacrolimus thymoglobulin .</brief_summary>
	<brief_title>Study Myfortic Combination With Tacrolimus Thymoglobulin Early Corticosteroid Withdrawal</brief_title>
	<detailed_description>Evaluate safety efficacy Myfortic combination tacrolimus anti-thymocyte globulin early corticosteroid withdrawal protocol . Secondary objective determine pharmacokinetic-pharmacodynamic profile Myfortic corticosteroid withdrawal protocol .</detailed_description>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>Males females 18 75 year age . Patients primary repeat cadaveric , live unrelated nonHLA identical living relate donor renal transplant recipient . Patient previously receive receive organ transplant kidney . Primary retransplant human leukocyte antigen ( HLA ) identical living donor . Recipient donor know seropositive hepatitis C virus ( HCV ) , hepatitis B virus ( HBV ) , human immunodeficiency virus ( HIV ) . Uncontrolled concomitant infection unstable medical condition . Patients receive investigational drug 30 day prior transplant . Known hypersensitivity tacrolimus , mycophenolate mofetil ( MMF ) , entericcoated mycophenolic acid , rabbit antithymocyte globulin , corticosteroid . Receiving chronic steroid therapy time transplant . History malignancy last 5 year . Pregnant lactating .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Kidney</keyword>
	<keyword>Transplant</keyword>
	<keyword>Corticosteroid</keyword>
	<keyword>Myfortic</keyword>
</DOC>